A hepatitis C virus (HCV) plasmid vaccine was constructed, based on class II-associated invariant chain peptide (CLIP) substitution which endogenously targets HCV non-structure protein 3 (NS3) CD4+ T helper 1(Th1) epitope (1248AA-1261AA) to major histocompatibility complex (MHC) class II antigen. The in vitro expression results demonstrated that the vaccine was expressed efficiently in COS-7 cell line. The expressed protein could co-localize in endo-membrane system with BALB/c mouse MHC class II molecule I-Ad. The recombinant invariant chain molecule could aggregate with BALB/c mouse I-Ad molecule and form the theoretical nonomer structure in the COS-7 cell line. The assembled molecules migrate to the cell surface by exocytosis. This has implications for HCV vaccine development.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s10529-005-4679-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Long term T cell response and safety of a tetravalent dengue vaccine in healthy children.
NPJ Vaccines
October 2024
Takeda Pharmaceuticals International AG, Zurich, Switzerland.
As robust cellular responses are important for protection against dengue, this phase 2 study evaluated the kinetics and phenotype of T cell responses induced by TAK-003, a live-attenuated tetravalent dengue vaccine, in 4-16-year-old living in dengue-endemic countries (NCT02948829). Two hundred participants received TAK-003 on Days 1 and 90. Interferon-gamma (IFN-γ) enzyme-linked immunospot assay [ELISPOT] and intracellular cytokine staining were used to analyze T cell response and functionality, using peptide pools representing non-structural (NS) proteins NS3 and NS5 matching DENV-1, -2, -3, and -4 and DENV-2 NS1.
View Article and Find Full Text PDFImmunization of recombinant NS3 protein (protease region) of dengue virus induces high levels of CTLA-4 and apoptosis in splenocytes of BALB/c mice.
Virus Genes
October 2024
LADISER Inmunología y Biología Molecular, Facultad de Ciencias Químicas, Edificio D, Universidad Veracruzana, Prolongación de Oriente 6 No. 1009, Col. Rafael Alvarado, 94340, Orizaba, Veracruz, Mexico.
DENV infection outcomes depend on the host's variable expression of immune receptors and mediators, leading to either resolution or exacerbation. While the NS3 protein is known to induce robust immune responses, the specific impact of its protease region epitopes remains unclear. This study investigated the effect of recombinant NS3 protease region proteins from all four DENV serotypes on splenocyte activation in BALB/c mice (n = 5/group).
View Article and Find Full Text PDFComparison of the inhibitory and stimulatory effects of Core and NS3 candidate HCV vaccines on the cellular immune response.
Am J Clin Exp Immunol
December 2023
Clinical Microbiology Research Center, Nemazee Hospital, Shiraz University of Medical Sciences Shiraz, Iran.
Article Synopsis
- Hepatitis C virus (HCV) affects about 3% of the global population, and while there are studies focused on vaccine development, no vaccines are currently available.
- Research indicates that successful HCV vaccination depends on specific immune responses, including CTL responses and T regulatory cells, with proteins Core and NS3 being key targets for vaccine design.
- In mouse models, the study demonstrated that a DNA vaccine incorporating NS3 showed better potential in enhancing immune activity and reducing inhibitory T regulatory cells compared to one incorporating Core, suggesting NS3 is a more effective candidate for HCV vaccine development.
Identification of T cell and linear B cell epitopes on African horse sickness virus serotype 4 proteins VP1-1, VP2, VP4, VP7 and NS3.
Vaccine
January 2024
Agricultural Research Council - Onderstepoort Veterinary Research, Private Bag X5, Onderstepoort 0110, South Africa; Department of Veterinary Tropical Diseases, Faculty of Veterinary Science, University of Pretoria, Private Bag X04, Onderstepoort 0110, South Africa.
The viral proteins VP1-1, VP2, VP4, VP7 and NS3, of African horse sickness virus serotype 4 (AHSV4), have previously been identified to contain CD8+ T cell epitopes. In this study, overlapping peptides spanning the entire sequences of these AHSV4 proteins were synthesized and used to map epitopes. Peripheral blood mononuclear cells (PBMC) isolated from five horses immunized with an attenuated AHSV4 were stimulated in vitro with the synthesized peptides.
View Article and Find Full Text PDFPhase I Trial of a Therapeutic DNA Vaccine for Preventing Hepatocellular Carcinoma from Chronic Hepatitis C Virus (HCV) Infection.
Cancer Prev Res (Phila)
March 2023
Mayo Clinic, Rochester, Minnesota.
Unlabelled: Chronic hepatitis C can lead to cirrhosis and hepatocellular carcinoma. We studied the safety and immunogenicity of a novel therapeutic hepatitis C virus (HCV) genotype 1a/1b consensus DNA vaccine, INO-8000, encoding HCV NS3, NS4A, NS4B, and NS5A proteins alone or co-administered with DNA-encoding IL12 (INO-9012), a human cytokine that stimulates cellular immune function, in individuals with chronic hepatitis C. This was a phase I, multisite dose-escalation trial with an expansion cohort evaluating doses of 0, 0.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!